Journal: Frontier Forum of Clinical Medicine DOI: 10.32629/ffcr.v4i3.21384
Abstract
碳青霉烯耐药肺炎克雷伯菌(Carbapenem-Resistant Klebsiella pneumoniae,CRKP)所致肺炎是临床常见的严重院内感染,具有高发病率、高死亡率及 治疗选择有限的特点,已成为全球公共卫生领域的重大挑战。头孢他啶阿维巴坦作为 一种新型β-内酰胺类抗生素与β- 内酰胺酶抑制剂的复方制剂,凭借其对CRKP的独特抗菌机制,在临床治疗中展现出显 著优势。本文结合近年来国内外相关研究成果及临床实践,对头孢他啶阿维巴坦治疗 CRKP肺炎的作用机制、临床疗效、耐药性现状、联合用药策略及特殊人群应用等新 进展进行系统综述,为临床合理用药、优化治疗方案及后续研究提供参考。
Keywords
头孢他啶阿维巴坦；碳青霉烯耐药肺炎克雷伯菌；肺炎；抗菌治疗；研究进展
Full Text
PDF - Viewed/Downloaded: 1 TimesReferences
[1] 孙淑红,胡晓峰,李春芝.350株耐碳青霉烯类肺炎克雷伯菌耐药特征及基于头孢他啶 /阿维巴坦的联合药敏试验报告[J].中华医院感染学杂志,2025,36(01):6-10.
[2] 李银花,牛建星,李喜元.注射用头孢他啶阿维巴坦钠单独使用对耐碳青霉烯类肺炎 克雷伯菌感染所致肺炎的治疗效果及安全性分析[J].中国医药,2025,20(04):530-534.
[3] 陈虹,康梅.肺炎克雷伯菌对碳青霉烯耐药机制及抗菌药物治疗策略[J].国际检验医 学杂志,2025,46(15):1867-1872+1878.
[4] 马宁,杨宏富,刘启龙.头孢他啶/阿维巴坦治疗碳青霉烯耐药的肺炎克雷伯菌肺部感 染效果观察[J].中华实用诊断与治疗杂志,2023,37(08):846-850.
[5] 龙大利,杨生鹏,兰波.头孢他啶阿维巴坦治疗肾移植术后多重耐药肺炎克雷伯菌感 染患者的临床疗效及其影响因素分析[J].临床合理用药,2023,16(33):61-64.
[6] 李程锦,张金炎,林立伟.头孢他啶/阿维巴坦治疗超高龄危重症患者碳青霉烯类耐药 肺炎克雷伯菌肺部感染的有效性研究[J].中国医药指南,2025,23(20):77-80.
[7] 王根柱,王小营,李忠东.1例头孢他啶阿维巴坦联合氨曲南治疗重症肺炎失败后的药 物治疗策略分析[J].药物流行病学杂志,2024,33(03):342-348.
[8] 陈清,竺嘉幸,谢小云.头孢他啶阿维巴坦治疗移植后碳青霉烯类耐药肺炎克雷伯菌 感染的临床应用进展[J].中国呼吸与危重监护杂志,2024,23(06):447-452.
[9] 余蓓蕾,王铮,李梦甜.头孢他啶- 阿维巴坦治疗终末期肾脏病患者合并耐碳青霉烯类肺炎克雷伯菌所致肺炎1例[J].江苏大 学学报(医学版),2025,35(01):76-78+85.
[10] 毛娇娇,曹国文,朱珠.头孢他啶- 阿维巴坦钠对碳青霉烯耐药的革兰阴性菌感染患者的临床疗效及其影响因素分析[J].抗 感染药学,2024,21(02):144-151.
[11] 赵圆祺,程明璟,熊苗苗.头孢他啶/阿维巴坦治疗耐碳青霉烯类肺炎克雷伯菌感染 的研究进展[J].中国感染控制杂志,2024,23(08):1047-1052.
[12] 伍碧武,黄晓岚,刘振洋.头孢他啶- 阿维巴坦治疗碳青霉烯类耐药肺炎克雷伯菌所致细菌性脑室炎及脑膜炎1例[J].中国感染 与化疗杂志,2024,24(01):80-84.
[13] 周吉欽,徐博,赵华容.头孢他啶阿维巴坦治疗耐碳青霉烯类革兰阴性杆菌感染致脑 室炎的文献分析[J].中国合理用药探索,2023,20(12):67-73.
[14] Lorena Galvão de Araújo,Fabianna Márcia Maranhão Bahia,Edilane Gouveia Voss,Joice Neves Reis Pedreira.BLOODSTREAM INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ENTEROBACTERALES:IMPACT OF CEFTAZIDIME-AVIBACTAM ANTIBIOTIC THERAPY ON LETHALITY[J].Brazilian Journal of Infectious Diseases,2025,30(S1):105395-105395.
[15] HaoTian Xu,Tingjuan Zhang,Xueying Cui,JingYi Guo,PengPeng Min,ChengJin Wu,XinYan Tang,LongJie Zhou,LinFang Wang,Xi Li.Development of ceftazidime-avibactam resistance driven by conversion of blaKPC-2 to blaKPC- 78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection.[J].International journal of antimicrobial agents,2025,67(2):107703.
[16] Karan R,Dhankhar K,Singh A,et al.Decoding Ceftazidime-Avibactam Resistance in Newly Identified Klebsiella pneumoniae Carbapenemase(KPC)107 Variant by Modulating the Active Site Environment[J].ACS Infectious Diseases,2025,11(12):3451-3465.
[17] Fang Ling Du,Dan Dan Wei,Yong Qing Guo,Peng Liu,Yan Fang Mei,Shan Shan Huang,Qi Sen Huang,Lin Ping Fan,Yang Liu.Emergence of blaKPC-71 variant and loss of aerobactin-encoding genes(iucABCD-iutA)in ST11-K64 carbapenem-resistant Klebsiella pneumoniae during ceftazidime-avibactam treatment.[J].Journal of global antimicrobial resistance,2025,46166-170.
[18] 马肖,胡超然,马立艳.头孢他啶- 阿维巴坦和依拉环素对耐碳青霉烯类肺炎克雷伯菌的体外抗菌活性分析[J].临床检验杂 志,2024,42(08):589-591.
[19] 郭晓龙,李激扬,徐菀佚.头孢他啶/阿维巴坦治疗耐碳青霉烯肺炎克雷伯菌致医院 获得性肺炎的成本-效果分析[J].中国药学杂志,2023,58(19):1783-1788.
[20] Jannatul Nazerin Rubaiat,Sourav Debnath,Mukesh Sharma,Ahmed Abu Saleh,Shaheda Anwar.Synergistic effect of ceftazidime-avibactam and aztreonam combination against carbapenem resistant Klebsiella spp.,E.coli and Pseudomonas spp.[J].Diagnostic microbiology and infectious disease,2025,114(3):117206.
[21] Thomas Lavoie,Teresa Sierra,Katie Daffinee,Jason M Pogue,Brahim Achour,Kerry LaPlante.Unlocking potentials:the impact of meropenem,meropenem-vaborbactam,and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.[J].Antimicrobial agents and chemotherapy,2025,e0090625.
[22] Pu Weicong,Fan Lili,Zhang Yudong,You Dianping,Li Mei,Ma Li.Carbapenem- resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.[J].The Pediatric infectious disease journal,2023,42(12):1124-1127.
[23] Xi Li,Longjie Zhou,Huaqiong Huang.Dynamic evolution of KPC-230- mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae[J].Drug Resistance Updates,2025,79101205-101205.
[24] 张梦怡,冯孟文,张倩.头孢他啶阿维巴坦治疗碳青霉烯类耐药铜绿假单胞菌感染的 疗效与安全性分析[J].南京医科大学学报(自然科学版),2023,43(08):1150-1155.
[25] Önal Uğur,TüzemenÜlkü,Kaya Pınar K,İşçimen Remzi,Girgin Nermin K,Özakın Cüneyt,Kahveci Ferda,Akalın Halis.OXA-48 Dominance Meets Ceftazidime-Avibactam:A Battle Against Life-Threatening Carbapenem- Resistant Klebsiella pneumoniae Infections in the Intensive Care Unit.[J].Cureus,2023,15(10):e46780-e46780.
[26] 毛小红,石佳娜,陈敏华.头孢他啶/阿维巴坦治疗危重症患者碳青霉烯类耐药革兰 阴性菌感染的一项回顾性研究[J].中国抗生素杂志,2025,50(12):1487-1495.
[27] 柴玉慧,杨云云,陈井霞.头孢他啶- 阿维巴坦治疗耐碳青霉烯类肠杆菌血流感染的有效性及安全性Meta分析[J].医药导报,2 024,43(10):1552-1561.
[28] Sree Racha Amarthya,Gupta Anand,Gupta Nitin,Veturi Sadhana,Reddy L Siva Kumar,Begum Masrath,Shravani Etrouth,Challa HariPriya Reddy,Reddy Satti Santhosh,Singamsetty Adarsh,Arumilli Murthy,Reddy P Naveen,Tirlangi Praveen Kumar.Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections(CAPRI study):a retrospective cohort study from South India.[J].Infection,2023,52(2):429-437.
[2] 李银花,牛建星,李喜元.注射用头孢他啶阿维巴坦钠单独使用对耐碳青霉烯类肺炎 克雷伯菌感染所致肺炎的治疗效果及安全性分析[J].中国医药,2025,20(04):530-534.
[3] 陈虹,康梅.肺炎克雷伯菌对碳青霉烯耐药机制及抗菌药物治疗策略[J].国际检验医 学杂志,2025,46(15):1867-1872+1878.
[4] 马宁,杨宏富,刘启龙.头孢他啶/阿维巴坦治疗碳青霉烯耐药的肺炎克雷伯菌肺部感 染效果观察[J].中华实用诊断与治疗杂志,2023,37(08):846-850.
[5] 龙大利,杨生鹏,兰波.头孢他啶阿维巴坦治疗肾移植术后多重耐药肺炎克雷伯菌感 染患者的临床疗效及其影响因素分析[J].临床合理用药,2023,16(33):61-64.
[6] 李程锦,张金炎,林立伟.头孢他啶/阿维巴坦治疗超高龄危重症患者碳青霉烯类耐药 肺炎克雷伯菌肺部感染的有效性研究[J].中国医药指南,2025,23(20):77-80.
[7] 王根柱,王小营,李忠东.1例头孢他啶阿维巴坦联合氨曲南治疗重症肺炎失败后的药 物治疗策略分析[J].药物流行病学杂志,2024,33(03):342-348.
[8] 陈清,竺嘉幸,谢小云.头孢他啶阿维巴坦治疗移植后碳青霉烯类耐药肺炎克雷伯菌 感染的临床应用进展[J].中国呼吸与危重监护杂志,2024,23(06):447-452.
[9] 余蓓蕾,王铮,李梦甜.头孢他啶- 阿维巴坦治疗终末期肾脏病患者合并耐碳青霉烯类肺炎克雷伯菌所致肺炎1例[J].江苏大 学学报(医学版),2025,35(01):76-78+85.
[10] 毛娇娇,曹国文,朱珠.头孢他啶- 阿维巴坦钠对碳青霉烯耐药的革兰阴性菌感染患者的临床疗效及其影响因素分析[J].抗 感染药学,2024,21(02):144-151.
[11] 赵圆祺,程明璟,熊苗苗.头孢他啶/阿维巴坦治疗耐碳青霉烯类肺炎克雷伯菌感染 的研究进展[J].中国感染控制杂志,2024,23(08):1047-1052.
[12] 伍碧武,黄晓岚,刘振洋.头孢他啶- 阿维巴坦治疗碳青霉烯类耐药肺炎克雷伯菌所致细菌性脑室炎及脑膜炎1例[J].中国感染 与化疗杂志,2024,24(01):80-84.
[13] 周吉欽,徐博,赵华容.头孢他啶阿维巴坦治疗耐碳青霉烯类革兰阴性杆菌感染致脑 室炎的文献分析[J].中国合理用药探索,2023,20(12):67-73.
[14] Lorena Galvão de Araújo,Fabianna Márcia Maranhão Bahia,Edilane Gouveia Voss,Joice Neves Reis Pedreira.BLOODSTREAM INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ENTEROBACTERALES:IMPACT OF CEFTAZIDIME-AVIBACTAM ANTIBIOTIC THERAPY ON LETHALITY[J].Brazilian Journal of Infectious Diseases,2025,30(S1):105395-105395.
[15] HaoTian Xu,Tingjuan Zhang,Xueying Cui,JingYi Guo,PengPeng Min,ChengJin Wu,XinYan Tang,LongJie Zhou,LinFang Wang,Xi Li.Development of ceftazidime-avibactam resistance driven by conversion of blaKPC-2 to blaKPC- 78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection.[J].International journal of antimicrobial agents,2025,67(2):107703.
[16] Karan R,Dhankhar K,Singh A,et al.Decoding Ceftazidime-Avibactam Resistance in Newly Identified Klebsiella pneumoniae Carbapenemase(KPC)107 Variant by Modulating the Active Site Environment[J].ACS Infectious Diseases,2025,11(12):3451-3465.
[17] Fang Ling Du,Dan Dan Wei,Yong Qing Guo,Peng Liu,Yan Fang Mei,Shan Shan Huang,Qi Sen Huang,Lin Ping Fan,Yang Liu.Emergence of blaKPC-71 variant and loss of aerobactin-encoding genes(iucABCD-iutA)in ST11-K64 carbapenem-resistant Klebsiella pneumoniae during ceftazidime-avibactam treatment.[J].Journal of global antimicrobial resistance,2025,46166-170.
[18] 马肖,胡超然,马立艳.头孢他啶- 阿维巴坦和依拉环素对耐碳青霉烯类肺炎克雷伯菌的体外抗菌活性分析[J].临床检验杂 志,2024,42(08):589-591.
[19] 郭晓龙,李激扬,徐菀佚.头孢他啶/阿维巴坦治疗耐碳青霉烯肺炎克雷伯菌致医院 获得性肺炎的成本-效果分析[J].中国药学杂志,2023,58(19):1783-1788.
[20] Jannatul Nazerin Rubaiat,Sourav Debnath,Mukesh Sharma,Ahmed Abu Saleh,Shaheda Anwar.Synergistic effect of ceftazidime-avibactam and aztreonam combination against carbapenem resistant Klebsiella spp.,E.coli and Pseudomonas spp.[J].Diagnostic microbiology and infectious disease,2025,114(3):117206.
[21] Thomas Lavoie,Teresa Sierra,Katie Daffinee,Jason M Pogue,Brahim Achour,Kerry LaPlante.Unlocking potentials:the impact of meropenem,meropenem-vaborbactam,and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.[J].Antimicrobial agents and chemotherapy,2025,e0090625.
[22] Pu Weicong,Fan Lili,Zhang Yudong,You Dianping,Li Mei,Ma Li.Carbapenem- resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.[J].The Pediatric infectious disease journal,2023,42(12):1124-1127.
[23] Xi Li,Longjie Zhou,Huaqiong Huang.Dynamic evolution of KPC-230- mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae[J].Drug Resistance Updates,2025,79101205-101205.
[24] 张梦怡,冯孟文,张倩.头孢他啶阿维巴坦治疗碳青霉烯类耐药铜绿假单胞菌感染的 疗效与安全性分析[J].南京医科大学学报(自然科学版),2023,43(08):1150-1155.
[25] Önal Uğur,TüzemenÜlkü,Kaya Pınar K,İşçimen Remzi,Girgin Nermin K,Özakın Cüneyt,Kahveci Ferda,Akalın Halis.OXA-48 Dominance Meets Ceftazidime-Avibactam:A Battle Against Life-Threatening Carbapenem- Resistant Klebsiella pneumoniae Infections in the Intensive Care Unit.[J].Cureus,2023,15(10):e46780-e46780.
[26] 毛小红,石佳娜,陈敏华.头孢他啶/阿维巴坦治疗危重症患者碳青霉烯类耐药革兰 阴性菌感染的一项回顾性研究[J].中国抗生素杂志,2025,50(12):1487-1495.
[27] 柴玉慧,杨云云,陈井霞.头孢他啶- 阿维巴坦治疗耐碳青霉烯类肠杆菌血流感染的有效性及安全性Meta分析[J].医药导报,2 024,43(10):1552-1561.
[28] Sree Racha Amarthya,Gupta Anand,Gupta Nitin,Veturi Sadhana,Reddy L Siva Kumar,Begum Masrath,Shravani Etrouth,Challa HariPriya Reddy,Reddy Satti Santhosh,Singamsetty Adarsh,Arumilli Murthy,Reddy P Naveen,Tirlangi Praveen Kumar.Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections(CAPRI study):a retrospective cohort study from South India.[J].Infection,2023,52(2):429-437.
Copyright © 2026 张询, 刘会前, 琚长斌
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License